Molecular biomedicine最新文献_第2页

Monoclonal antibodies: From magic bullet to precision weapon. 单克隆抗体：从神奇子弹到精确武器

IF 6.3

Molecular biomedicine Pub Date : 2024-10-11 DOI: 10.1186/s43556-024-00210-1

Hassan Aboul-Ella, Asmaa Gohar, Aya Ahmed Ali, Lina M Ismail, Adham Ezz El-Regal Mahmoud, Walid F Elkhatib, Heba Aboul-Ella

{"title":"Monoclonal antibodies: From magic bullet to precision weapon.","authors":"Hassan Aboul-Ella, Asmaa Gohar, Aya Ahmed Ali, Lina M Ismail, Adham Ezz El-Regal Mahmoud, Walid F Elkhatib, Heba Aboul-Ella","doi":"10.1186/s43556-024-00210-1","DOIUrl":"10.1186/s43556-024-00210-1","url":null,"abstract":"Monoclonal antibodies (mAbs) are used to prevent, detect, and treat a broad spectrum of non-communicable and communicable diseases. Over the past few years, the market for mAbs has grown exponentially with an expected compound annual growth rate (CAGR) of 11.07% from 2024 (237.64 billion USD estimated at the end of 2023) to 2033 (679.03 billion USD expected by the end of 2033). Ever since the advent of hybridoma technology introduced in 1975, antibody-based therapeutics were realized using murine antibodies which further progressed into humanized and fully human antibodies, reducing the risk of immunogenicity. Some benefits of using mAbs over conventional drugs include a drastic reduction in the chances of adverse reactions, interactions between drugs, and targeting specific proteins. While antibodies are very efficient, their higher production costs impede the process of commercialization. However, their cost factor has been improved by developing biosimilar antibodies as affordable versions of therapeutic antibodies. Along with the recent advancements and innovations in antibody engineering have helped and will furtherly help to design bio-better antibodies with improved efficacy than the conventional ones. These novel mAb-based therapeutics are set to revolutionize existing drug therapies targeting a wide spectrum of diseases, thereby meeting several unmet medical needs. This review provides comprehensive insights into the current fundamental landscape of mAbs development and applications and the key factors influencing the future projections, advancement, and incorporation of such promising immunotherapeutic candidates as a confrontation approach against a wide list of diseases, with a rationalistic mentioning of any limitations facing this field.","PeriodicalId":74218,"journal":{"name":"Molecular biomedicine","volume":null,"pages":null},"PeriodicalIF":6.3,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142402276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Ulcerative colitis: molecular insights and intervention therapy. 溃疡性结肠炎：分子研究与干预治疗。

IF 6.3

Molecular biomedicine Pub Date : 2024-10-10 DOI: 10.1186/s43556-024-00207-w

Yuqing Liang, Yang Li, Chehao Lee, Ziwei Yu, Chongli Chen, Chao Liang

{"title":"Ulcerative colitis: molecular insights and intervention therapy.","authors":"Yuqing Liang, Yang Li, Chehao Lee, Ziwei Yu, Chongli Chen, Chao Liang","doi":"10.1186/s43556-024-00207-w","DOIUrl":"10.1186/s43556-024-00207-w","url":null,"abstract":"Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by abdominal pain, diarrhea, rectal bleeding, and weight loss. The pathogenesis and treatment of UC remain key areas of research interest. Various factors, including genetic predisposition, immune dysregulation, and alterations in the gut microbiota, are believed to contribute to the pathogenesis of UC. Current treatments for UC include 5-aminosalicylic acids, corticosteroids, immunosuppressants, and biologics. However, study reported that the one-year clinical remission rate is only around 40%. It is necessary to prompt the exploration of new treatment modalities. Biologic therapies, such as anti-TNF-α monoclonal antibody and JAK inhibitor, primarily consist of small molecules targeting specific pathways, effectively inducing and maintaining remission. Given the significant role of the gut microbiota, research into intestinal microecologics, such as probiotics and prebiotics, and fecal microbiota transplantation (FMT) shows promising potential in UC treatment. Additionally, medicinal herbs, such as chili pepper and turmeric, used in complementary therapy have shown promising results in UC management. This article reviews recent findings on the mechanisms of UC, including genetic susceptibility, immune cell dynamics and cytokine regulation, and gut microbiota alterations. It also discusses current applications of biologic therapy, herbal therapy, microecologics, and FMT, along with their prospects and challenges.","PeriodicalId":74218,"journal":{"name":"Molecular biomedicine","volume":null,"pages":null},"PeriodicalIF":6.3,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11464740/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142395768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathways regulating intestinal stem cells and potential therapeutic targets for radiation enteropathy. 调节肠干细胞的途径和辐射性肠病的潜在治疗靶点

IF 6.3

Molecular biomedicine Pub Date : 2024-10-10 DOI: 10.1186/s43556-024-00211-0

Si-Min Chen, Bing-Jie Guo, An-Qiang Feng, Xue-Lian Wang, Sai-Long Zhang, Chao-Yu Miao

{"title":"Pathways regulating intestinal stem cells and potential therapeutic targets for radiation enteropathy.","authors":"Si-Min Chen, Bing-Jie Guo, An-Qiang Feng, Xue-Lian Wang, Sai-Long Zhang, Chao-Yu Miao","doi":"10.1186/s43556-024-00211-0","DOIUrl":"10.1186/s43556-024-00211-0","url":null,"abstract":"Radiotherapy is a pivotal intervention for cancer patients, significantly impacting their treatment outcomes and survival prospects. Nevertheless, in the course of treating those with abdominal, pelvic, or retroperitoneal malignant tumors, the procedure inadvertently exposes adjacent intestinal tissues to radiation, posing risks of radiation-induced enteropathy upon reaching threshold doses. Stem cells within the intestinal crypts, through their controlled proliferation and differentiation, support the critical functions of the intestinal epithelium, ensuring efficient nutrient absorption while upholding its protective barrier properties. Intestinal stem cells (ISCs) regulation is intricately orchestrated by diverse signaling pathways, among which are the WNT, BMP, NOTCH, EGF, Hippo, Hedgehog and NF-κB, each contributing to the complex control of these cells' behavior. Complementing these pathways are additional regulators such as nutrient metabolic states, and the intestinal microbiota, all of which contribute to the fine-tuning of ISCs behavior in the intestinal crypts. It is the harmonious interplay among these signaling cascades and modulating elements that preserves the homeostasis of intestinal epithelial cells (IECs), thereby ensuring the gut's overall health and function. This review delves into the molecular underpinnings of how stem cells respond in the context of radiation enteropathy, aiming to illuminate potential biological targets for therapeutic intervention. Furthermore, we have compiled a summary of several current treatment methodologies. By unraveling these mechanisms and treatment methods, we aspire to furnish a roadmap for the development of novel therapeutics, advancing our capabilities in mitigating radiation-induced intestinal damage.","PeriodicalId":74218,"journal":{"name":"Molecular biomedicine","volume":null,"pages":null},"PeriodicalIF":6.3,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467144/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142402277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

HJURP sustains ferroptosis sensitivity of TNBC by interacting with SLC7A11 and maintaining its function. HJURP 通过与 SLC7A11 相互作用并维持其功能，维持 TNBC 的铁蛋白沉积敏感性。

IF 6.3

Molecular biomedicine Pub Date : 2024-10-03 DOI: 10.1186/s43556-024-00208-9

Yongxia Chen, Kaili Cen, Linbo Wang, Jian Ruan, Yunlu Jia

引用次数: 0

Repurposing metabolic regulators: antidiabetic drugs as anticancer agents. 代谢调节剂的再利用：作为抗癌药物的抗糖尿病药物。

IF 6.3

Molecular biomedicine Pub Date : 2024-09-28 DOI: 10.1186/s43556-024-00204-z

Yogita Dhas, Nupur Biswas, Divyalakshmi M R, Lawrence D Jones, Shashaanka Ashili

{"title":"Repurposing metabolic regulators: antidiabetic drugs as anticancer agents.","authors":"Yogita Dhas, Nupur Biswas, Divyalakshmi M R, Lawrence D Jones, Shashaanka Ashili","doi":"10.1186/s43556-024-00204-z","DOIUrl":"https://doi.org/10.1186/s43556-024-00204-z","url":null,"abstract":"Drug repurposing in cancer taps into the capabilities of existing drugs, initially designed for other ailments, as potential cancer treatments. It offers several advantages over traditional drug discovery, including reduced costs, reduced development timelines, and a lower risk of adverse effects. However, not all drug classes align seamlessly with a patient's condition or long-term usage. Hence, repurposing of chronically used drugs presents a more attractive option. On the other hand, metabolic reprogramming being an important hallmark of cancer paves the metabolic regulators as possible cancer therapeutics. This review emphasizes the importance and offers current insights into the repurposing of antidiabetic drugs, including metformin, sulfonylureas, sodium-glucose cotransporter 2 (SGLT2) inhibitors, dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists (GLP-1RAs), thiazolidinediones (TZD), and α-glucosidase inhibitors, against various types of cancers. Antidiabetic drugs, regulating metabolic pathways have gained considerable attention in cancer research. The literature reveals a complex relationship between antidiabetic drugs and cancer risk. Among the antidiabetic drugs, metformin may possess anti-cancer properties, potentially reducing cancer cell proliferation, inducing apoptosis, and enhancing cancer cell sensitivity to chemotherapy. However, other antidiabetic drugs have revealed heterogeneous responses. Sulfonylureas and TZDs have not demonstrated consistent anti-cancer activity, while SGLT2 inhibitors and DPP-4 inhibitors have shown some potential benefits. GLP-1RAs have raised concerns due to possible associations with an increased risk of certain cancers. This review highlights that further research is warranted to elucidate the mechanisms underlying the potential anti-cancer effects of these drugs and to establish their efficacy and safety in clinical settings.","PeriodicalId":74218,"journal":{"name":"Molecular biomedicine","volume":null,"pages":null},"PeriodicalIF":6.3,"publicationDate":"2024-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11436690/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142333937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Oncolytic adenovirus encoding decorin and CD40 ligand inhibits tumor growth and liver metastasis via immune activation in murine colorectal tumor model. 在小鼠结直肠肿瘤模型中，编码Decolin和CD40配体的溶瘤腺病毒通过免疫激活抑制肿瘤生长和肝转移。

IF 6.3

Molecular biomedicine Pub Date : 2024-09-22 DOI: 10.1186/s43556-024-00202-1

Yejing Rong, Yingjun Ning, Jianping Zhu, Pei Feng, Weixin Zhu, Xin Zhao, Zi Xiong, Chunyan Ruan, Jiachang Jin, Hua Wang, Ting Cai, Shun Zhang, Yuefeng Yang

{"title":"Oncolytic adenovirus encoding decorin and CD40 ligand inhibits tumor growth and liver metastasis via immune activation in murine colorectal tumor model.","authors":"Yejing Rong, Yingjun Ning, Jianping Zhu, Pei Feng, Weixin Zhu, Xin Zhao, Zi Xiong, Chunyan Ruan, Jiachang Jin, Hua Wang, Ting Cai, Shun Zhang, Yuefeng Yang","doi":"10.1186/s43556-024-00202-1","DOIUrl":"10.1186/s43556-024-00202-1","url":null,"abstract":"Colorectal cancer (CRC) is the second common cause of cancer mortality worldwide, and it still lacks effective approaches for relapsed and metastatic CRC. Recently, oncolytic virus has been emerged as a promising immune therapeutic strategy. In this study, we develop a novel oncolytic adenovirus, rAd.mDCN.mCD40L, which drive oncolytic activity by telomerase reverse transcriptase promoter (TERTp). rAd.mDCN.mCD40L expressed both mouse genes of decorin (mDCN) and CD40 ligand (mCD40L), and produced effective cytotoxicity in both human and mouse CRC cells. Moreover, oncolytic adenovirus mediated mDCN over-expression inhibited Met expression in vitro. In CT26 subcutaneous tumor model, intratumorally delivery of oncolytic adenoviruses could inhibit tumor growth and liver metastasis, while mDCN and/or mCD40L armed oncolytic adenoviruses produced much more impressive responses. No obvious toxicity was detected in lung, liver and spleen. Moreover, mDCN and/or mCD40L armed oncolytic adenoviruses altered the immune state to activate anti-tumor responses, including increasing CD8+ T effector cells and CD4+ memory T cells, reducing MDSCs and Tregs in peripheral blood. Furthermore, mDCN and/or mCD40L armed oncolytic adenoviruses mediated mDCN and/or mCD40L expression in tumors, and up-regulated Th1 cytokines and reduced Th2 cytokines in tumors, which will be benefit for remodeling tumor microenvironment. Importantly, rAd.mDCN.mCD40L and rAd.mCD40L prevented tumor liver metastasis much more effectively than rAd.Null and rAd.mDCN. Therefore, rAd.mDCN.mCD40L and rAd.mCD40L are promising approaches for CRC therapy.","PeriodicalId":74218,"journal":{"name":"Molecular biomedicine","volume":null,"pages":null},"PeriodicalIF":6.3,"publicationDate":"2024-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11416448/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The dual role of SOX17 in the occurrence and development of early colorectal cancer. SOX17 在早期结直肠癌的发生和发展中的双重作用。

IF 6.3

Molecular biomedicine Pub Date : 2024-09-16 DOI: 10.1186/s43556-024-00201-2

Xinming Su, Jianqiao Shentu, Ruixiu Chen, Shiwei Duan

引用次数: 0

Gut microbiome influences efficacy of Endostatin combined with PD-1 blockade against colorectal cancer. 肠道微生物组影响内司他丁联合 PD-1 阻断剂对结直肠癌的疗效。

IF 6.3

Molecular biomedicine Pub Date : 2024-09-10 DOI: 10.1186/s43556-024-00200-3

Jie Xu, Yaomei Tian, Binyan Zhao, Die Hu, Siwen Wu, Jing Ma, Li Yang

{"title":"Gut microbiome influences efficacy of Endostatin combined with PD-1 blockade against colorectal cancer.","authors":"Jie Xu, Yaomei Tian, Binyan Zhao, Die Hu, Siwen Wu, Jing Ma, Li Yang","doi":"10.1186/s43556-024-00200-3","DOIUrl":"10.1186/s43556-024-00200-3","url":null,"abstract":"The combination of anti-angiogenic drugs and immune checkpoint inhibitors (ICIs) in the treatment of tumors is emerging as a way to improve ICIs-resistant tumor therapy. In addition, gut microbes (GMs) are involved in angiogenesis in the tumor microenvironment and are also associated with the antitumor function of immune checkpoint inhibitors. However, it is unclear whether gut microbes have a role in anti-tumor function in the combination of anti-angiogenic drugs and immune checkpoint inhibitors for cancer treatment. Endostatin, an angiogenesis inhibitor, has been widely used as an antiangiogenic therapy for cancer. We showed that combined therapy with an adenovirus encoding human endostatin, named Ad-E, and PD-1 blockade dramatically abrogated MC38 tumor growth. The structure of intestinal microbes in mice was changed after combination treatment. We found that the antitumor function of combination therapy was inhibited after the elimination of intestinal microbes. In mice with depleted microbiota, oral gavage of Bacteroides fragilis salvaged the antitumor effects of combination Ad-E and αPD-1 monoclonal antibody (mAb) to a certain extent. Further, Bacteroides fragilis could improve CD3+T cells, NK cells, and IFNγ+CD8+ T cells in the tumor microenvironment to inhibit tumor growth. Besides, Bacteroides fragilis might restore antitumor function by down-regulating isobutyric acid (IBA). Our results suggested that GMs may be involved in the combination of Ad-E and αPD-1 mAb for cancer treatment, which has oncological implications for tumor growth dynamics and cancer immune surveillance.","PeriodicalId":74218,"journal":{"name":"Molecular biomedicine","volume":null,"pages":null},"PeriodicalIF":6.3,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11383918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302785","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SOX7 inhibits the malignant progression of bladder cancer via the DNMT3B/CYGB axis. SOX7 通过 DNMT3B/CYGB 轴抑制膀胱癌的恶性进展。

IF 6.3

Molecular biomedicine Pub Date : 2024-09-04 DOI: 10.1186/s43556-024-00198-8

Jingcheng Zhang, Wentao Zhang, Ji Liu, Yuchao Liu, Yufeng Jiang, Ailiyaer Ainiwaer, Hanyang Chen, Zhuoran Gu, Haotian Chen, Shiyu Mao, Yadong Guo, Tianyuan Xu, Yunfei Xu, Yuan Wu, Xudong Yao, Yang Yan

{"title":"SOX7 inhibits the malignant progression of bladder cancer via the DNMT3B/CYGB axis.","authors":"Jingcheng Zhang, Wentao Zhang, Ji Liu, Yuchao Liu, Yufeng Jiang, Ailiyaer Ainiwaer, Hanyang Chen, Zhuoran Gu, Haotian Chen, Shiyu Mao, Yadong Guo, Tianyuan Xu, Yunfei Xu, Yuan Wu, Xudong Yao, Yang Yan","doi":"10.1186/s43556-024-00198-8","DOIUrl":"10.1186/s43556-024-00198-8","url":null,"abstract":"Bladder cancer (BCa) stands out as a highly prevalent malignant tumor affecting the urinary system. The Sex determining region Y-box protein family is recognized for its crucial role in BCa progression. However, the effect of Sex determining region Y-box 7 (SOX7) on BCa progression has not been fully elucidated. Herein, RNA-sequencing, western blot (WB), immunohistochemistry (IHC), immunofluorescence (IF) and tissue microarray were utilized to assess SOX7 expression in vitro and in vivo. Additionally, SOX7 expression, prognosis, and SOX7 + cytoglobin (CYGB) score were analyzed using R software. In vitro and vivo experiments were performed with BCa cell lines to validate the effect of SOX7 knockdown and overexpression on the malignant progression of BCa. The results showed that SOX7 exhibits low expression in BCa. It functions in diverse capacities, inhibiting the proliferative, migratory, and invasive capabilities of BCa. In addition, the experimental database demonstrated that SOX7 binds to the promoter of DNA methyltransferase 3 beta (DNMT3B), leading to the transcriptional inhibition of DNMT3B. This subsequently results in a reduced methylation of CYGB promoter, ultimately inhibiting the tumor progression of BCa. SOX7 + CYGB scores were significantly linked to patient prognosis. In conclusion, SOX7 inhibits the malignant progression of BCa via the DNMT3B/CYGB axis. Additionally, the SOX7 + CYGB score is capable of predicting the prognostic outcomes of BCa patients. Therefore, SOX7 and CYGB may play an important role in the progression of bladder cancer, and they can be used as prognostic markers of bladder cancer patients.","PeriodicalId":74218,"journal":{"name":"Molecular biomedicine","volume":null,"pages":null},"PeriodicalIF":6.3,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11371982/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A review of HSV pathogenesis, vaccine development, and advanced applications. HSV 发病机制、疫苗开发和先进应用综述。

IF 6.3

Molecular biomedicine Pub Date : 2024-08-29 DOI: 10.1186/s43556-024-00199-7

Lan Bai, Jiuzhi Xu, Linghui Zeng, Long Zhang, Fangfang Zhou

{"title":"A review of HSV pathogenesis, vaccine development, and advanced applications.","authors":"Lan Bai, Jiuzhi Xu, Linghui Zeng, Long Zhang, Fangfang Zhou","doi":"10.1186/s43556-024-00199-7","DOIUrl":"10.1186/s43556-024-00199-7","url":null,"abstract":"Herpes simplex virus (HSV), an epidemic human pathogen threatening global public health, gains notoriety for its complex pathogenesis that encompasses lytic infection of mucosal cells, latent infection within neurons, and periodic reactivation. This intricate interplay, coupled with HSV's sophisticated immune evasion strategies, gives rise to various diseases, including genital lesions, neonatal encephalitis, and cancer. Despite more than 70 years of relentless research, an effective preventive or therapeutic vaccine against HSV has yet to emerge, primarily due to the limited understanding of virus-host interactions, which in turn impedes the identification of effective vaccine targets. However, HSV's unique pathological features, including its substantial genetic load capacity, high replicability, transmissibility, and neurotropism, render it a promising candidate for various applications, spanning oncolytic virotherapy, gene and immune therapies, and even as an imaging tracer in neuroscience. In this review, we comprehensively update recent breakthroughs in HSV pathogenesis and immune evasion, critically summarize the progress made in vaccine candidate development, and discuss the multifaceted applications of HSV as a biological tool. Importantly, we highlight both success and challenges, emphasizing the critical need for intensified research into HSV, with the aim of providing deeper insights that can not only advance HSV treatment strategies but also broaden its application horizons.","PeriodicalId":74218,"journal":{"name":"Molecular biomedicine","volume":null,"pages":null},"PeriodicalIF":6.3,"publicationDate":"2024-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11362470/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142115646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0